SCHEMBL25613071

SCHEMBL25613071

CC(C)(C)c1cc2cc[nH]c2nc1OCCN1CC(O)C1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LTA4H P09960 2/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ CYP2D6 P10635 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ HSD17B10 Q99714 1/20 0.33
▸ JAK1 P23458 3/20 0.32
▸ JAK2 O60674 2/20 0.32
▸ TYK2 P29597 2/20 0.32
▸ JAK3 P52333 2/20 0.32
▸ FEN1 P39748 1/20 0.32
▸ EGFR P00533 1/20 0.32
▸ HTR7 P34969 6/20 0.31
▸ HTR1A P08908 4/20 0.31
▸ ALDH1A1 P00352 2/20 0.31
▸ SYK P43405 2/20 0.31
▸ DRD2 P14416 1/20 0.31
▸ DRD3 P35462 1/20 0.31
▸ KDM4E B2RXH2 1/20 0.30
▸ GAA P10253 1/20 0.30
▸ PIK3CD O00329 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25613054 0.85 LTA4H (0.45) LTA4HCYP1A2CYP2D6CYP2C19HSD17B10
SCHEMBL25613068 0.82 CYP3A4 (0.45) CYP2D6JAK1ALDH1A1SYKKDM4E
SCHEMBL25613050 0.80 FEN1 (0.39) FEN1SYKGAAPIK3CD
SCHEMBL25613045 0.77 ULK1 (0.39) FEN1
SCHEMBL25613335 0.77 FEN1 (0.39) FEN1PIK3CD
SCHEMBL25613057 0.76 KDM4E (0.39) FEN1ALDH1A1KDM4EGAA
SCHEMBL25613037 0.75 FEN1 (0.39) FEN1PIK3CD
SCHEMBL25613056 0.75 KDM4E (0.39) CYP1A2CYP2D6FEN1HTR7ALDH1A1
SCHEMBL25613078 0.74 PIK3CD (0.33) JAK3FEN1PIK3CD
SCHEMBL25613043 0.72 CDK1 (0.39) FEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159527-A1 COMPOUNDS AS BCL-2 INHIBITORS FOCHON BIOSCIENCES, LTD. (CN) 2023-05-25 — — US disclosed
US-20230159527-A1 COMPOUNDS AS BCL-2 INHIBITORS FOCHON BIOSCIENCES, LTD. (CN) 2023-05-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159527-A1 COMPOUNDS AS BCL-2 INHIBITORS BCL2, BCL2L2, BCL2L1 LTA4H 4604/4885CYP1A2 2573/4885CYP2D6 3553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback